Previous 10 | Next 10 |
EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conf...
Adamas Pharmaceuticals ( ADMS +4.5% ) announces new post-hoc Phase 3 data showing that Gocovri decreased dyskinesia and OFF time (periods where levodopa therapy is not working well) in people with Parkinson’s Disease (PD). More news on: Adamas Pharmaceuticals, Inc., He...
EMERYVILLE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced its presentation of a new post-hoc pivo...
Xeris Pharma Reports Positive Topline Data for Insulin Trial Xeris Pharmaceuticals ( XERS ) reported positive data for its Phase 2 clinical trial for diabetes. The drug candidate XP-3924 is an o-formulation of pramlintide and insulin and the trial aimed to assess its potential in treati...
Gainers: ELOX +52.1% . ORN +17.7% . TMBR +8.5% . ABM +8.0% . DADA +7.2% . More news on: Eloxx Pharmaceuticals, Inc., Orion Group Holdings, Inc., Timber Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Citing "limited" commercial opportunity and the need to conduct another late-stage clinical trial, Adamas Pharmaceuticals (NASDAQ: ADMS ) has decided to terminate development of ADS-5102 (amantadine) extended-release capsules for the treatment multiple sclerosis (MS) patients with walkin...
EMERYVILLE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of AD...
Heron Reports Positive Results From Mid-Stage Knee Replacement Trial Heron Therapeutics (HRTX) announced that its Phase 2b clinical trial Study 209 has provided positive data with regard to HTX-011. The trial involved testing the drug candidate on patients undergoing total knee arthropla...
The FDA accepts for review Adamas Pharmaceuticals' (NASDAQ: ADMS ) supplemental marketing application seeking approval to use Gocovri (amantadine) to treat OFF episodes in Parkinson's disease (PD) patients receiving levodopa-based therapy. The agency's action date is February 1, 2021....
EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Applica...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...